Patients with non-small cell lung cancer (NSCLC) with specific mutations in the tyrosine kinase domain of the epidermal growth factor (EGFR) gene have favorable clinical outcomes with EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy [4]. The gene discussed is EGF; the disease is non-small cell lung carcinoma.